Introduction {#s0005}
============

Renal cell carcinoma (RCC) accounts for about 2% to 3% of all malignant diseases in adults with clear cell RCC (ccRCC) being the most common histologic subtype that represents 70% to 80% of all cases [@bb0005]. Despite the emergence of novel targeted therapies such as antiangiogenetic drugs and mammalian target of rapamycin inhibitors over the last decade, the prognosis of metastatic renal cancer remains poor with 5-year survival rates of less than 10% [@bb0010]. This grim prognosis poses the need for a better understanding of the underlying molecular mechanisms driving metastatic ccRCC to be able to develop novel therapeutic approaches.

The Hippo signaling pathway has been found to be evolutionary conserved and to function as a critical regulator of organ size control. Moreover, we and others have recently been able to show that Hippo signaling exerts a dramatic oncogenic potential in several human malignancies [@bb0015], [@bb0020]. Although germ-line and somatic mutations of the Hippo pathway core components are rare, deregulation and subsequent overexpression of Yes-associated protein (YAP) have been observed in many human cancers [@bb0025], [@bb0030], [@bb0035]. However, as of to date, little data exist on the role of Hippo signaling in ccRCC.

In this study, we demonstrate that Hippo signaling is activated in ccRCC and is involved in regulating proliferation, invasiveness, and metastatic potential. Downstream effectors of Hippo signaling in ccRCC are characterized to identify potential targets for therapeutic intervention.

Materials and Methods {#s0010}
=====================

Tumor Samples and Immunohistochemistry {#s0015}
--------------------------------------

All tumor samples were collected from the archives of the Institute of Pathology, University of Cologne (Cologne, Germany). The samples were formalin fixed and paraffin embedded (FFPE) as part of routine diagnostic procedures. Clinicopathologic data were obtained from case records provided by the Institute of Pathology, University of Cologne. All tumors were clinically and pathologically identified as being the primary and only neoplastic lesion and classified according to World Health Organization guidelines. Briefly, 3-μm-thick sections of FFPE tumors were deparaffinized, and antigen retrieval was performed by boiling the section in citrate buffer at pH 6 for 20 minutes. Primary antibodies used were given as follows: YAP (1:100, \#4912; Cell Signaling Technology, Danvers, MA), endothelin-2 (EDN2; 1:100, NBP1-87942; Novus Biologicals, Littleton, CO), SAV1 (1:100, clone 3B3; Abnova, Taipei, Taiwan), and cytokeratin (1:200, clone AE1/AE3; Dako, Glostrup, Denmark). Staining was performed following established routine procedures, and staining intensity was evaluated individually in a blinded fashion. Statistical analysis was performed using Fisher exact test on GraphPad\'s QuickCalcs platform (<http://graphpad.com/quickcalcs/contingency1.cfm>). *P* \< .05 was considered statistically significant.

Cell Lines {#s0020}
----------

Human RCC cell lines A498 (ATCC HTB-44), Caki-2 (ATCC HTB-47), MZ1774, B1, B3, and RCC177 were cultured in RPMI 1640 (PAA Laboratories, Pasching, Austria), supplemented with 10% FBS, 1 × penicillin/streptomycin (both PAA Laboratories), as well as 5 μg/ml plasmocin (InvivoGen, San Diego, CA). MZ1774, B1, B3, and RCC177 are primary RCC cell lines and have been described in [@bb0040], [@bb0045], [@bb0050]. The human RCC cell line ACHN (ATCC CRL-1611) was maintained in Dulbecco\'s modified Eagle\'s medium (PAA Laboratories) supplemented with 10% FBS, 1 × penicillin/ streptomycin (both PAA Laboratories), and 5 μg/ml plasmocin (InvivoGen).

293FT cells were maintained in Dulbecco\'s modified Eagle\'s medium containing 10% FBS, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, and 1 × penicillin/ streptomycin (all PAA Laboratories) as well as 5 μg/ml plasmocin (InvivoGen).

All cell lines were cultured in a humidified atmosphere at 37°C in the presence of 5% CO~2~ and were regularly monitored for *Mycoplasma* infection using a polymerase chain reaction (PCR)--based assay as previously described [@bb0055].

Lentivirus Production and Generation of Stable Cell Lines {#s0025}
---------------------------------------------------------

A target set containing shRNA sequences directed against human YAP1 in pLKO.1 lentiviral plasmids was obtained from Thermo Scientific (Waltham, MA), and two clones, which had shown best knockdown efficiency in preliminary experiments, were selected for lentiviral transduction of ccRCC cell lines, designated YAPshRNA\#4 (Clone No. TRCN0000107268) and YAPshRNA\#5 (Clone No. TRCN0000107269).

293FT-packaging cells were cotransfected with pCMV-VSVg, pCMV-dR8.74, and the respective pLKO.1 plasmids using Fugene6 (Roche Applied Science, Mannheim, Germany). An empty pLKO.1 vector containing no shRNA sequence was used as a negative "mock" control. Supernatant containing lentivirus was harvested after 48 and 72 hours and used to transduce human ccRCC cell lines. Puromycin selection of resistant ccRCC cells was performed, and cells were cultured in the presence of puromycin throughout all experiments.

Cell Viability Assays {#s0030}
---------------------

Determination of cell viability was performed using the 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2*H*-tetrazolium (MTS) assay as previously described [@bb0060]. Briefly, 2000 cells per well were incubated in full growth media for 0, 48, or 96 hours, respectively. All experiments were set up in quadruplicates, and results were normalized to the mean cell viability at 0 hour. CellTiter 96 Aqueous One solution (20 μl; Promega, Madison, WI) was added to each well and absorbance at 492 nm was determined using a 96-well plate reader (BMG Labtech, Offenburg, Germany) on incubation of plates at 37°C for 2 hours.

Replating Efficiency Assays {#s0035}
---------------------------

Cells were seeded into six-well plates at 1000 cells per well in full growth media. Once colonies became visible, cells were fixed with 70% ethanol and stained with a 0.05% aqueous solution of crystal violet (Sigma-Aldrich, Steinheim, Germany). Colonies were counted and colony counts were normalized to the mean colony count of mock-transduced cell lines.

Soft Agar Assays {#s0040}
----------------

Soft agar assays were set up in six-well plates with a bottom layer of 1% agarose (Life Technologies, Darmstadt, Germany), an intermediate layer containing 0.6% agarose and 10,000 cells per well, as well as a final layer of media only. Plates were incubated for 4 weeks at 37°C and medium was exchanged once weekly. Colonies were stained with a 0.05% aqueous solution of crystal violet (Sigma-Aldrich) and visualized by trans-UV illumination (Bio-Rad, Hercules, CA). Colonies were counted and colony counts were normalized to the mean colony count of mock-transduced cell lines.

Migration Assays {#s0045}
----------------

Modified Boyden chamber assays were set up in 24-well transwell plates with 8-μm pore size filters (BD Biosciences, San Jose, CA). Fifty thousand cells per well were applied and transwell migration was assessed after 48 and 72 hours of incubation at 37°C, respectively. Cells adherent at the bottom of the filter were fixed in 70% ethanol and stained with hematoxylin. Cells were counted in three randomly selected microscopic fields and means and SDs were calculated.

Western Blot {#s0050}
------------

Cells were lysed in radioimmunoprecipitation assay buffer (1% Igepal CA 630, 0.5% Na-deoxycholate, 0.1% sodium dodecyl sulfate, 2 mM EDTA) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Fifty micrograms of total protein was separated on sodium dodecyl sulfate--polyacrylamide gels and transferred onto nitrocellulose membranes (Merck Millipore, Billerica, MA). The blots were probed with antibodies against YAP, phospho-YAP (pYAP), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology) as well as TEAD1 (Santa Cruz Biotechnology, Dallas, TX). Secondary, HRP-coupled antibodies directed against rabbit or mouse IgG, respectively, were purchased from Cell Signaling Technology. Detection was performed as previously described [@bb0065].

Transcriptomic Profiling of MZ1774 YAP Knockdown Cells {#s0055}
------------------------------------------------------

A total of 100 ng of total RNA, isolated using the RNeasy Kit (Qiagen, Hilden, Germany) following the standard procedure as recommended by the manufacturer, was subjected to a single round of *in vitro* transcription and biotin labeling (Illumina TotalPrep RNA Amplification Kit; Ambion, Austin, TX). The resulting complementary RNA was hybridized on HumanHT-12 v4.0 Expression BeadArrays (Illumina, San Diego, CA) according to the manufacturer\'s protocols using an automated liquid handling pipeline and scanned on an iScan System.

Expression data were exported as unnormalized sample and control probe profiles from the Illumina GenomeStudio software and analyzed using R/Bioconductor and limma. Data were quality weighed, background-corrected, quantile-normalized, log-transformed, and explored for differentially expressed genes with a false discovery rate (FDR) of 0.05 using Bayesian statistics. Differential regulation of signaling pathways was performed using the signaling pathway impact analysis algorithm as previously described elsewhere [@bb0070].

RNA Extraction and Reverse Transcription--Quantitative PCR {#s0060}
----------------------------------------------------------

For real-time reverse transcription--quantitative PCR (RT-qPCR) analysis, cells were lysed and total RNA was extracted using RNeasy Mini Kit including an on-column DNase digestion step (both Qiagen). RNA was reverse transcribed using random primers and the High Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the manufacturer\'s specifications. Real-time qPCR for human YAP, endothelin-1 (EDN1), EDN2, V-myc myelocytomatosis viral oncogene homolog (avian) (MYC), cadherin-6 (CDH6), cysteine-rich, angiogenic inducer, 61 (CYR61), thrombospondin-1 (THBS1), and growth arrest and DNA damage-inducible, beta was performed using the SYBR Premix Ex Taq (Tli RNase H Plus) Kit (Takara Bio Europe, Saint-Germain-en-Laye, France) on a Reaplex^2^ Mastercycler Real-Time PCR System (Eppendorf, Hamburg, Germany). Relative fold expression levels were determined using the 2(− ΔΔ*C*~t~) method [@bb0075], with GAPDH used as a housekeeping control.

Chromatin Immunoprecipitation {#s0065}
-----------------------------

TEAD1-binding sites found in 5 kb upstream of the transcription start site of the indicated genes were considered and primer pairs for qPCR measurement of immunoprecipitated promoter fragments flanking the putative binding regions were designed. Chromatin from formaldehyde cross-linked MZ1774 cells was isolated and sheared to an average fragment size of 600 bp using a probe sonicator (Branson Ultrasonics, Danbury CT). Aliquots of pre-cleared, diluted chromatin was immunoprecipitated using antibodies against YAP or TEAD1 (both Santa Cruz Biotechnology), and immunoprecipitated fragments were pulled down using protein A agarose beads. Immunoprecipitations using normal mouse IgG (Santa Cruz Biotechnology) as well as anti-acetyl histone H3 (Merck Millipore) were carried out simultaneously as negative and positive controls. Immunoprecipitated DNA fragments were purified using the phenol/chloroform method and RT-qPCR for the putative binding regions was performed on all chromatin immunoprecipitation (ChIP) preparations. Fold enrichments were calculated in relation to the negative controls using normal mouse IgG.

Xenograft Experiments {#s0070}
---------------------

All animal experiments described were approved by the Government of the State of North Rhine-Westphalia (Permit No. 8.87-50.10.37.09.264). Mice were maintained according to the guidelines of the Federation of European Laboratory Animal Science Associations.

To generate subcutaneous xenografts, ACHN YAP knockdown and ACHN mock-transfected cells in log growth phase were harvested by trypsinization, counted, and subsequently injected into the flanks of five male athymic CD1^nu/nu^ mice (Charles River, Wilmington, MA) as previously described [@bb0080]. In brief, 2.5 × 10^6^ cells suspended in a total volume of 250 μl \[full growth medium/Matrigel (BD Biosciences), 1:1 (vol/vol), prechilled to 4°C\] were subcutaneously injected into the flanks of 6- to 8-week-old mice. Starting 10 days after the injection of tumor cells, tumor dimensions were determined twice a week by use of digital calipers (Milomex, Pulloxhill, United Kingdom), and tumor volumes (*V*) were determined as *V* = 1/2(*ab*^2^), with *a* being the longest and *b* the shortest orthogonal tumor diameter. Mice were sacrificed after 6 weeks, and tumors were harvested and cryopreserved or formalin-fixed for later analysis.

Statistical Analysis {#s0075}
--------------------

Fisher exact test and two-tailed Student\'s *t*-tests were done using GraphPad Prism for Macintosh, version 4.0a. *P* \< .05 was regarded to be statistically significant. Unless indicated otherwise, results are shown as means ± SEM.

Results {#s0080}
=======

The Hippo Pathway Effector Yes-Associated Protein Is Overexpressed in ccRCC {#s0085}
---------------------------------------------------------------------------

In a panel of seven ccRCC cell lines, basal YAP expression was found in all cell lines examined, although expression levels varied greatly, with some cell lines expressing very high levels of YAP, while expression was minimal in others. The phosphorylated form of the transcriptional coactivator constitutes the inactive form of YAP. We found that cell lines with high basal levels of total YAP contained minimal (ACHN) to absent (MZ1774) levels of pYAP pointing toward high transcriptional activity of YAP. We further found consistently high levels of TEAD1, a major interaction partner of YAP, in all cell lines analyzed ([Figure 1](#f0005){ref-type="fig"}).Figure 1Expression of YAP in ccRCC cell lines. Basal expression of YAP was observed in all ccRCC cell lines examined, whereas expression of the inactive form pYAP was minimal to absent in cell lines expressing high basal levels of YAP. The transcription factor TEAD1, a major interaction partner of YAP, was found in all ccRCC cell lines analyzed.

Next, expression of the Hippo pathway component SAV1 and of the nuclear effector of the Hippo pathway YAP was assessed in 31 ccRCC cases by immunohistochemistry. In non-neoplastic renal parenchyma, we observed strong nuclear YAP expression in podocytes and differential expression in the proximal and distal compartments of the renal tubules. While the distal segments of the renal tubule consistently exhibited strong cytoplasmic and nuclear immunolabeling, significantly weaker YAP expression was observed in the proximal tubules, the putative site of origin of ccRCC ([Figure 2](#f0010){ref-type="fig"}, *A* and *B*). In RCC tissue samples, we found nuclear up-regulation of YAP expression compared to the proximal tubules in the adjacent normal tissue in 20 of 31 cases (65%; *P* \< .0001).Figure 2Loss of SAV1 expression results in nuclear sequestration of YAP in patients with ccRCC, and coexpression of YAP and keratin is associated with a highly invasive phenotype. Immunohistochemistry of tumor tissues of 31 patients with ccRCC showed distinct staining of normal renal parenchyma with proximal tubule cells exhibiting only minimal to weak nuclear staining (A), whereas most tumors showed moderate to strong YAP immunoreactivity (B). YAP positivity was stronger at the tumor margins (C) and highlights single cells invading tumor-adjacent stroma (D, F) that also exhibit positivity for cytokeratin (E, G). Loss of SAV1 immunoreactivity was frequently associated with sequestration of YAP expression to the nucleus of tumor cells (J, K), whereas retained SAV1 expression results in mainly cytoplasmic YAP expression (H, I).

Of note, YAP staining intensity was considerably more prominent at the tumor margins representing the invasive front, and in several patients that showed high expression levels of YAP, we observed single keratin-positive tumor cells invading the surrounding lymphocyte rich stroma, suggesting a possible role of Hippo signaling in ccRCC tumor cell invasion *in vivo* ([Figure 2](#f0010){ref-type="fig"}, *C*--*G*).

We cannot report correlation of YAP positivity with tumor grade based on this small sample size, with 22 of 31 cases being histopathologically classified as grade 2. However, vascular invasion or lymph node metastases were reported for 9 of 30 cases, and of these, 7 exhibited marked YAP positivity.

Loss of SAV1 Immunoreactivity Correlates with Nuclear Localization of YAP {#s0090}
-------------------------------------------------------------------------

Immunohistochemistry revealed strong cytoplasmic SAV1 expression in normal tubular epithelial cells, but curiously immunolabeling was lost in adjacent neoplastic cells in 16 of 31 cases. Moreover, weak or absent SAV1 expression was found to correlate with nuclear localization of YAP, whereas sustained SAV1 expression *vice versa* caused nuclear exclusion of YAP (*P* = .0091; see [Table 1](#t0005){ref-type="table"} and [Figure 2](#f0010){ref-type="fig"}, *H*--*K*).Table 1Loss of SAV1 Immunoreactivity Correlates with Nuclear Localization of YAP.YAP ExpressionCytoplasmicNuclearTotalSAV1Positive13215Weak or negative61016Total191231[^1]

shRNA-Mediated Knockdown of YAP Impairs Proliferation and Blocks Migration of ccRCC Cells *In Vitro* {#s0095}
----------------------------------------------------------------------------------------------------

To further study the role of Hippo signaling in renal cell cancer and to evaluate its potential as a putative therapeutic target, three ccRCC cell lines with high basal YAP expression levels---A498, ACHN, and MZ1774---were picked and dysfunctional Hippo signaling and aberrant YAP activity were abrogated by shRNA-mediated knockdown. For each of the respective parental cell lines, at least two different shRNA sequences directed against YAP (designated as "YAPshRNA\#4" and "YAPshRNA\#5") were used and compared to untransduced as well as to mock-transduced mass clones to minimize the risk of unspecific, off-target effects. Consistent stable knockdown of endogenous YAP was confirmed by Western blot analysis ([Figure 3](#f0015){ref-type="fig"}*A*).Figure 3YAP down-regulation impairs proliferation and migration of ccRCC cell lines. shRNA-mediated knockdown of YAP in three different ccRCC cell lines that express high levels of YAP (A) resulted in significantly reduced cell viability as determined by MTS assay (B). YAP down-regulation further resulted in marked inhibition of ccRCC migration in modified Boyden chamber assays. Transwell migration through 8-μm pore filters was assessed after 48 and 72 hours. A pronounced decrease in cell numbers was found for the YAP knockdown mass clones. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 (C). Three randomly selected microscopic fields of representative experiments were selected and cells were counted. Results are shown as means ± SD.

In all of the three cell lines examined, YAP knockdown led to a significant time-dependent reduction of net cell growth compared to mock-transduced cells as determined using MTS assays ([Figure 3](#f0015){ref-type="fig"}*B*).

Next, effects of YAP knockdown on *in vitro* cell migration was assessed by employing modified Boyden chamber assays. Of note, a marked reduction of ccRCC migration was observed in response to YAP knockdown in all three cell lines examined (*P* \< .001; [Figure 3](#f0015){ref-type="fig"}*C*), in line with the observation of YAP being associated to an invasive phenotype *in vivo*, as already discussed above. All experiments were done in triplicates and repeated at least once.

YAP Knockdown Diminishes Colony Formation and Anchorage-Independent Growth of ccRCC Cells {#s0100}
-----------------------------------------------------------------------------------------

The ability to form colonies from single cells and the ability to grow anchorage independently are considered two important hallmarks of cancer cells *in vitro*. To determine potential effects of YAP knockdown on the former of these cellular functions in ccRCC, replating efficiency assays were performed using single cell suspensions. Of note, the ability of ACHN-YAP-shRNA\#4 cells to form colonies from single cells in this setting was significantly reduced compared to mock-transduced ACHN controls (mean reduction of colony counts by 66.3 ± 0.05%, *n* = 6, *P* \< .0001; [Figure 4](#f0020){ref-type="fig"}*A*). Of interest, the colonies formed by YAP knockdown cells were not only less numerous but also smaller in size, reflecting reduced *in vitro* net cell growth as already observed previously in MTS assays.Figure 4shRNA-mediated YAP knockdown reduces colony formation and abates anchorage-independent growth of ccRCC cells. Down-regulation of YAP significantly reduced the number of colonies formed in replating efficiency assays (A) as well as anchorage-independent growth in soft agar of the ccRCC cell line ACHN (B). Representative images and combined colony counts of three independent experiments are shown.

Anchorage-independent growth and colony formation in soft agar is a widely accepted *in vitro* surrogate phenotype for malignant transformation. YAP knockdown potently and reproducibly abrogated anchorage-independent growth of ACHN cells in soft agar (reduction of colony counts by more than 90 ± 0.02%, *n* = 6, *P* \< .0001; [Figure 4](#f0020){ref-type="fig"}*B*). Similar to what was seen in replating assays, the remaining colonies formed by ACHN-YAP-shRNA mass clones were not only sparse in number but also significantly smaller compared to their mock-transduced counterparts in this three-dimensional culture setting.

YAP Knockdown Inhibits Tumor Growth in a Subcutaneous Xenograft Model of ccRCC {#s0105}
------------------------------------------------------------------------------

On the basis of these encouraging *in vitro* data suggesting a dependency of ccRCC cells on signaling through the Hippo pathway for maintenance of a malignant phenotype, we next tried to assess the *in vivo* relevance of this finding using a subcutaneous xenograft model. Male athymic CD1^nu/nu^ nude mice, 6 to 8 weeks of age, were injected subcutaneously with 2.5 × 10^6^ ACHN-YAP-shRNA or ACHN mock cells into both flanks. Tumor volumes were assessed weekly using digital calipers starting 1 week after injection. Of note, xenograft growth of ACHN-YAP-shRNA cells was significantly delayed compared to ACHN mock controls (*P* = .0182; [Figure 6](#f0030){ref-type="fig"}, *A*, *left panel*, and *B*), while at the same time the overall body mass of xenograft-bearing mice was not significantly altered between the two study arms ([Figure 6](#f0030){ref-type="fig"}*A*, *right panel*).

At 5 weeks after injection, mice were sacrificed, and tumors were harvested for histopathologic and immunohistochemical evaluation or snap-frozen for mRNA extraction and subsequent real-time RT-qPCR analysis, respectively.

Microarray Analysis of MZ1774 YAP Knockdown Cells Identifies Putative Downstream Targets of YAP in ccRCC {#s0110}
--------------------------------------------------------------------------------------------------------

cDNA microarray analysis of MZ1774 YAPshRNA mass clones revealed 14 genes that were upregulated more than two-fold ([Table 2](#t0010){ref-type="table"}) and another 42 genes that were downregulated by more than 50% compared to mock-transfected MZ1774 cells ([Table 3](#t0015){ref-type="table"}). Of these, eight targets were picked for validation by real-time qPCR. All of those eight targets found to be downregulated by microarray analysis were confirmed to be downregulated using RT-qPCR, and CDH6 as an example of a target found to be overexpressed in the microarray analysis was also found to be upregulated using RT-qPCR ([Figure 5](#f0025){ref-type="fig"}*A*).Figure 5Differential expression of selected genes was confirmed by real-time RT-qPCR. The graphs show normalized average steady-state mRNA expression levels in YAPshRNA-transfected *versus* mock-transfected MZ1774 cells as means and SEM (A). Cross-validation in other YAPshRNA-transfected ccRCC cell lines revealed uniform EDN2, CYR61, and THBS1 down-regulation as well as EDN1 and cMYC down-regulation in two tested cell lines (B). YAP and TEAD1 are simultaneously present on selected TEAD1-binding sites in the promoter regions of CTGF, MYC, EDN1, and EDN2 (C, D).Table 2Upregulated Genes in MZ1774 YAP Knockdown Cells.Gene IDSymbolGene NameAccession No.Fold Change*P* Value84952*CGNL1Cingulin-like 1*[NM_001252335.1](ncbi-n:NM_001252335.1){#ir0340}2.972.23E−115265*SERPINA1Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1*[NM_000295.4](ncbi-n:NM_000295.4){#ir0345}2.496.10E−0780117*ARL14ADP-ribosylation factor-like 14*[NM_025047.2](ncbi-n:NM_025047.2){#ir0350}2.491.91E−0710344*CCL26Chemokine (C-C motif) ligand 26*[NM_006072.4](ncbi-n:NM_006072.4){#ir0355}2.472.00E−051004*CDH6Cadherin-6, type 2, K-cadherin (fetal kidney)*[NM_004932.3](ncbi-n:NM_004932.3){#ir0360}2.277.61E−10266977*GPR110G protein--coupled receptor 110*[NM_153840.2](ncbi-n:NM_153840.2){#ir0365}2.225.90E−07283460*HNF1A-AS1HNF1A antisense RNA 1 (non-protein coding)*[NR_024345.1](ncbi-n:NR_024345.1){#ir0370}2.112.20E−0455195*C14orf105Chromosome 14 open reading frame 105*[NM_018168.2](ncbi-n:NM_018168.2){#ir0375}2.074.97E−03266977*GPR110G protein--coupled receptor 110*[NM_153840.2](ncbi-n:NM_153840.2){#ir0380}2.061.09E−0611074*TRIM31Tripartite motif containing 31*[NM_007028.3](ncbi-n:NM_007028.3){#ir0385}2.041.00E−0555775*TDP1Tyrosyl DNA phosphodiesterase 1*[NM_001008744.1](ncbi-n:NM_001008744.1){#ir0390}2.037.20E−04283209*PGM2L1Phosphoglucomutase 2-like 1*[NM_173582.3](ncbi-n:NM_173582.3){#ir0395}2.025.00E−055265*SERPINA1Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1*[NM_000295.4](ncbi-n:NM_000295.4){#ir0400}2.021.30E−0411221*DUSP10Dual specificity phosphatase 10*[NM_007207.4](ncbi-n:NM_007207.4){#ir0405}2.011.00E−043767*KCNJ11Potassium inwardly rectifying channel, subfamily J, member 16*[NM_000525.3](ncbi-n:NM_000525.3){#ir0410}1.971.00E−052353*FOSFBJ murine osteosarcoma viral oncogene homolog B*[NM_005252.3](ncbi-n:NM_005252.3){#ir0415}1.975.91E−0256829*ZC3HAV1Zinc finger CCCH-type, antiviral 1*[NM_020119.3](ncbi-n:NM_020119.3){#ir0420}1.971.50E−04158295*MGC24103Hypothetical MGC24103*[XR_108934.3](ncbi-n:XR_108934.3){#ir0425}1.964.91E−037327*UBE2G2Ubiquitin-conjugating enzyme E2G2*[NM_003343.5](ncbi-n:NM_003343.5){#ir0430}1.958.77E−0356664*VTRNA1-1Vault RNA 1-1*[NR_026703.1](ncbi-n:NR_026703.1){#ir0435}1.941.20E−04Table 3Downregulated Genes in MZ1774 YAP Knockdown Cells.Gene IDSymbolGene NameAccession No.Fold Change*P* Value1907*EDN2Endothelin-2*[NM_001956.3](ncbi-n:NM_001956.3){#ir0440}0.241.16E−111906*EDN1Endothelin-1*[NM_001955.4](ncbi-n:NM_001955.4){#ir0445}0.318.57E−067057*THBS1Thrombospondin-1*[NM_003246.2](ncbi-n:NM_003246.2){#ir0450}0.332.34E−054616*GADD45BGrowth arrest and DNA-damage-inducible, beta*[NM_015675.3](ncbi-n:NM_015675.3){#ir0455}0.347.53E−053491*CYR61Cysteine-rich, angiogenic inducer, 61*[NM_001554.4](ncbi-n:NM_001554.4){#ir0460}0.361.73E−0410175*CNIHCornichon homolog (Drosophila)*[NM_005776.2](ncbi-n:NM_005776.2){#ir0465}0.373.02E−061646*AKR1C2Aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)*[NM_001354.5](ncbi-n:NM_001354.5){#ir0470}0.374.71E−064609*MYCV-myc myelocytomatosis viral oncogene homolog (avian)*[NM_002467.4](ncbi-n:NM_002467.4){#ir0475}0.371.05E−06523*ATP6V1AATPase, H^+^ transporting, lysosomal 70 kDa, V1 subunit A*[NM_001690.3](ncbi-n:NM_001690.3){#ir0480}0.384.44E−124609*MYCV-myc myelocytomatosis viral oncogene homolog (avian)*[NM_002467.4](ncbi-n:NM_002467.4){#ir0485}0.382.34E−066520*SLC3A2Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2*[NM_001012662.2](ncbi-n:NM_001012662.2){#ir0490}0.393.40E−06284018*C17orf58Chromosome 17 open reading frame 58*[NM_181655.2](ncbi-n:NM_181655.2){#ir0495}0.397.44E−1010413*YAP1Yes-associated protein 1*[NM_001130145.2](ncbi-n:NM_001130145.2){#ir0500}0.402.42E−0881788*NUAK2NUAK family, SNF1-like kinase, 2*[NM_030952.1](ncbi-n:NM_030952.1){#ir0505}0.404.10E−051316*KLF6Kruppel-like factor 6*[NM_001160124.1](ncbi-n:NM_001160124.1){#ir0510}0.404.23E−04586*BCAT1Branched chain amino acid transaminase 1, cytosolic*[NM_001178091.1](ncbi-n:NM_001178091.1){#ir0515}0.417.35E−0881788*NUAK2NUAK family, SNF1-like kinase, 2*[NM_030952.1](ncbi-n:NM_030952.1){#ir0520}0.415.60E−066526*SLC5A3Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3*[NM_006933.4](ncbi-n:NM_006933.4){#ir0525}0.411.85E−0759345*GNB4Guanine nucleotide binding protein (G protein), beta polypeptide 4*[NM_021629.3](ncbi-n:NM_021629.3){#ir0530}0.422.34E−0854206*ERRFI1ERBB receptor feedback inhibitor 1*[NM_018948.3](ncbi-n:NM_018948.3){#ir0535}0.424.98E−0927032*ATP2C1ATPase, Ca^++^ transporting, type 2C, member 1*[NM_001199180.1](ncbi-n:NM_001199180.1){#ir0540}0.422.63E−0784706*GPT2Glutamic pyruvate transaminase (alanine aminotransferase) 2*[NM_001142466.1](ncbi-n:NM_001142466.1){#ir0545}0.444.04E−089518*GDF15Growth differentiation factor 15*[NM_004864.2](ncbi-n:NM_004864.2){#ir0550}0.448.31E−05406991*MIR21MicroRNA 21*[NR_029493.1](ncbi-n:NR_029493.1){#ir0555}0.444.12E−0759272*ACE2Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2*[NM_021804.2](ncbi-n:NM_021804.2){#ir0560}0.442.76E−078140*SLC7A5Solute carrier family 7 (amino acid transporter light chain, L system), member 5*[NM_003486.5](ncbi-n:NM_003486.5){#ir0565}0.449.39E−0751125*GOLGA7Golgin A7*[NM_001002296.1](ncbi-n:NM_001002296.1){#ir0570}0.441.41E−114703*NEBNebulin*[NM_001164507.1](ncbi-n:NM_001164507.1){#ir0575}0.442.93E−0579660*PPP1R3BProtein phosphatase 1, regulatory (inhibitor) subunit 3B*[NM_001201329.1](ncbi-n:NM_001201329.1){#ir0580}0.444.58E−0610175*CNIHCornichon homolog (Drosophila)*[NM_005776.2](ncbi-n:NM_005776.2){#ir0585}0.452.71E−0557761*TRIB3Tribbles homolog 3 (Drosophila)*[NM_021158.3](ncbi-n:NM_021158.3){#ir0590}0.468.68E−06388272*C16orf87Chromosome 16 open reading frame 87*[NM_001001436.2](ncbi-n:NM_001001436.2){#ir0595}0.461.76E−066185*RPN2Ribophorin II*[NM_002951.3](ncbi-n:NM_002951.3){#ir0600}0.461.28E−0727063*ANKRD1Ankyrin repeat domain 1 (cardiac muscle)*[NM_014391.2](ncbi-n:NM_014391.2){#ir0605}0.472.80E−0629968*PSAT1Phosphoserine aminotransferase 1*[NM_021154.3](ncbi-n:NM_021154.3){#ir0610}0.471.45E−042152*F3Coagulation factor III (thromboplastin, tissue factor)*[NM_001993.4](ncbi-n:NM_001993.4){#ir0615}0.474.45E−0681539*SLC38A1Solute carrier family 38, member 1*[NM_001077484.1](ncbi-n:NM_001077484.1){#ir0620}0.481.17E−046397*SEC14L1SEC14-like 1 (S. cerevisiae)*[NM_001039573.2](ncbi-n:NM_001039573.2){#ir0625}0.483.67E−0810397*NDRG1N-myc downstream regulated 1*[NM_001135242.1](ncbi-n:NM_001135242.1){#ir0630}0.485.34E−065638*PRRG1Proline rich Gla (G-carboxyglutamic acid) 1*[NM_000950.2](ncbi-n:NM_000950.2){#ir0635}0.485.42E−0810797*MTHFD2methylenetetrahydrofolate dehydrogenase (NADP^+^ dependent) 2, methenyltetrahydrofolate cyclohydrolase*[NM_006636.3](ncbi-n:NM_006636.3){#ir0640}0.497.56E−082530*FUT8Fucosyltransferase 8 (alpha (1,6) fucosyltransferase)*[NM_178155.2](ncbi-n:NM_178155.2){#ir0645}0.493.76E−0780115*BAIAP2L2BAI1-associated protein 2-like 2*[NM_025045.4](ncbi-n:NM_025045.4){#ir0650}0.491.06E−055209*PFKFB36-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3*[NM_004566.3](ncbi-n:NM_004566.3){#ir0655}0.493.49E−0510175*CNIHCornichon homolog (Drosophila)*[NM_005776.2](ncbi-n:NM_005776.2){#ir0660}0.502.86E−05

Increasing recent evidence suggests that the complexity of cancer genomic and transcriptomic patterns might only be fully appreciated in its entirety when moving away from analyzing abnormalities on a single-gene basis and toward a pathway-based approach. This fundamental paradigm shift is currently being more and more commonly adapted and is finding its way into basic understanding of cancer research as well as into everyday routine clinical applications in the field of medical oncology [@bb0085], [@bb0090]. To identify signaling pathways potentially affected by altered signaling through the Hippo/warts axis, signaling pathway impact analysis was performed as previously described elsewhere [@bb0070]. Of note, the top three pathways found to be affected were the p53, MAP kinase, as well as cell cycle progression pathways, all of which have long been well established as centrally involved in carcinogenesis and maintenance of a malignant phenotype across several tumor entities ([Table 4](#t0020){ref-type="table"}). These findings thus further support our hypothesis that Hippo signaling might be a crucial driver of carcinogenesis and represents a promising potential therapeutic target in ccRCC.Table 4Signaling Pathways Affected by Knockdown of YAP in MZ1774 Cells.KEGG PathwayIDpNDEpPERTpGpGFDRpGFWERStatusKEGG Linkp53 signaling pathway41151.524E−060.12603.1620E−060.00030.0003Activatedhttp://www.genome.jp/dbget-bin/show_pathway?hsa04115+3486+1647+4616+7057+8795+54205+1021+27244MAPK signaling pathway40101.829E−040.31506.2009E−040.02480.0670Inhibitedhttp://www.genome.jp/dbget-bin/show_pathway?hsa04010+11221+2247+627+9261+1649+51776+1647+4616+3554+4609+2872Cell cycle41106.475E−020.00106.8925E−040.02480.0744Activatedhttp://www.genome.jp/dbget-bin/show_pathway?hsa04110+1647+4616+1021+4609[^2]

Among the most prominently downregulated genes were two members of the endothelin family, *EDN1* and *EDN2*, as well as *c-Myc*. Cross-validation of mRNA expression of these genes in MZ1774, A498, and ACHN YAP knockdown cells confirmed significant *c-Myc* and *EDN1* down-regulation in MZ1774 and A498 on YAP knockdown (MZ1774: fold changes = 0.34 ± 0.006, *P* \< .0001 for *c-Myc* and 0.41 ± 0.009, *P* \< .0001 for *EDN1*; A498: fold changes = 0.79 ± 0.026, *P* = .0085 for *c-Myc* and 0.41 ± 0.019, *P* = .0001 for *EDN1*, respectively; see [Figure 5](#f0025){ref-type="fig"}*B*). *EDN2* expression was significantly reduced in all three cell lines examined (fold changes = 0.06 ± 0.003, *P* \< .0001 for MZ1774, 0.62 ± 0.025, *P* = .001 for A498, and 0.17 ± 0.0067, *P* \< .0001 for ACHN, respectively).

Of note, immunohistochemistry and real-time RT-qPCR confirmed consistent knockdown of YAP1 as well as down-regulation of EDN2, both at the mRNA and protein levels, respectively, in murine xenografts of human ccRCCs as well ([Figure 6](#f0030){ref-type="fig"}, *C* and *D*).Figure 6YAP down-regulation inhibits tumor growth in a subcutaneous xenograft model. Subcutaneous injection of YAP knockdown cells into the flanks of CD1^nu/nu^ mice resulted in significantly smaller tumors compared to mock-transduced cells while not affecting the body mass of the mice (A, B). RT-PCR of freshly frozen xenograft tissue confirmed significant down-regulation of YAP and EDN2 in tumors derived from ACHN YAP knockdown cells (C). Hematoxylin and eosin stainings and immunohistochemistry of YAP and EDN2 in ACHN mock and ACHN YAP knockdown xenograft tissues illustrate down-regulation on the protein level (D). Representative images are shown in × 20, with insets in × 40 magnification.

To investigate a direct relationship between YAP and its putative target genes in ccRCC, we performed ChIP-qPCR on selected regions containing TEAD-binding motifs within the promoter region of those genes ([Figure 5](#f0025){ref-type="fig"}*C*). A well-characterized YAP/TEAD1-binding site in the promoter region of the *bona fide* YAP target gene *CTGF* was selected as a positive control. We found YAP and TEAD to be simultaneously present on the promoter regions of the *MYC*, *EDN1*, as well as *EDN2* genes in MZ1774 ([Figure 5](#f0025){ref-type="fig"}*D*).

YAP Expression Correlates with EDN2 Expression in ccRCC Tumors {#s0115}
--------------------------------------------------------------

We next analyzed the expression of the thus identified proposed downstream effector of YAP, EDN2, in primary tissue samples of human ccRCC tumors using immunohistochemistry. YAP expression was found to significantly correlate with positivity for EDN2 (*P* = .0067; [Table 5](#t0025){ref-type="table"}). [Figure 7](#f0035){ref-type="fig"} shows representative examples of two cases exhibiting double positivity (*A* and *B*) or double negativity (*C* and *D*) for YAP and EDN2, respectively.Figure 7EDN2 expression correlates with YAP positivity in patients with ccRCC. Immunohistochemistry of tumor tissues of 30 patients with ccRCC confirmed that EDN2 expression correlates with YAP positivity. Double positivity for YAP and EDN2 was frequently observed (A, B), whereas loss of YAP expression often results in minimal to absent EDN2 expression (C, D).Table 5Correlation of YAP and EDN2 Expression in ccRCC Tumors.YAP ExpressionPositiveWeak or NegativeTotalEDN2Positive20323Weak or negative257Total22830[^3]

Finally, [Figure 8](#f0040){ref-type="fig"} summarizes our results and proposes a potential mechanism of the proproliferative and proinvasive functions of YAP in ccRCC by its interaction with the endothelin axis and the tumor microenvironment.Figure 8Putative interaction of YAP with the endothelin axis in ccRCC.

Discussion {#s0120}
==========

Our data presented here suggest widespread deregulation of the Hippo signaling pathway in human ccRCC. In a considerable subset of cases, this was found to be due to down-regulation of the upstream regulator SAV1 and consecutive nuclear accumulation of YAP. In this regard, our data are in line with a recent report by Matsuura and colleagues, who describe down-regulation of SAV1 in high-grade ccRCC [@bb0095]. Of note, copy number loss on chromosome 14q22, i.e., in the region of the *SAV1* gene, have been previously described in high-grade ccRCC by different groups [@bb0095], [@bb0100], [@bb0105]. In addition, truncating mutations of this upstream member of the Hippo network are present in a subset of VHL-wt ccRCCs [@bb0110], [@bb0115]. However, our data presented here also hint at the existence of other alternative mechanisms of pathway perturbation in human ccRCC, since in a considerable subset of cases in which marked, albeit not exclusively nuclear staining for YAP was observed this was not accompanied by loss of SAV1 expression.

Moreover, our data suggest an important role of Hippo signaling in mediating proliferation as well as migration and invasion, both *in vitro* and *in vivo*, with obvious impact on the metastatic potential of ccRCC. In line with our observations, conditional knockout of NF2, an upstream activator of the growth inhibitory Hippo pathway, in the proximal tubular epithelium of Villin-Cre;Nf2^(lox/lox)^ mice leads to intratubular neoplasia and invasive carcinoma that resembles human RCC in a mouse model of RCC [@bb0120]. Recent reports also linked the renal cilia-associated proteins NPHP4 and NPHP9 to Hippo signaling in both oncogenically transformed and normal kidney epithelial cells. These proteins were found to prevent Lats-dependent phosphorylation of YAP, thus controlling YAP activation and mediating cell proliferation [@bb0125], [@bb0130]. Of note, Lamar et al. recently described enhanced metastatic potential of breast cancer as well as melanoma cells with increased YAP/TEAD activity; they concluded that YAP can promote metastasis through its TEAD-interaction domain [@bb0135]. To the best of our knowledge, our data presented here for the first time hint at a possible link between Hippo signaling and increased invasiveness and metastatic potential in ccRCC.

As a next step, we thought to further dissect the underlying mechanism by which YAP exerts its proproliferative and potentially proinvasive properties in ccRCC on a molecular level and to identify downstream effectors of Hippo signaling in this entity, since this might have important implications in exploiting this pathway as potential therapeutic target in future work. Transcriptomic profiling of MZ1774 YAP knockdown cells provided clues toward downstream targets of YAP in ccRCC, including some genes that are known to be overexpressed in ccRCC like members of the endothelin family, c-Myc, and CDH6, and has been shown to promote tumor growth and metastasis in experimental settings. We observed consistent down-regulation of the *bona fide* YAP target gene *CYR61* on YAP knockdown in all cell lines examined. CYR61 is a positive regulator of cell growth [@bb0140] and has been implicated as a proangiogenic factor in highly vascularized RCC, acting alongside vascular endothelial growth factor (VEGF) and exerting additive nonoverlapping functions [@bb0145]. CYR61 up-regulation correlated with loss of von Hippel-Lindau protein expression, although its expression was only partly dependent on Hypoxia-inducible factor 2-alpha function, suggesting additional mechanisms that contribute to CYR61 up-regulation in RCC [@bb0145]. Furthermore, recent reports linked CYR61 with integrin-mediated cell migration and invasion in prostate cancer cell lines, hinting at a potential role in metastasis [@bb0150].

THBS1 is one of the most potent physiological antiangiogenic factors and its expression has been reported as an independent prognostic factor in ccRCC with retained expression being associated with increased survival [@bb0155]. It is therefore somewhat surprising to observe down-regulation of THBS1 mRNA on YAP knockdown in all cell lines analyzed. YAP might interfere with the network of proangiogenic and antiangiogenic factors, such as CYR61 and THBS1, in ccRCC, tipping the balance toward a homeostasis that favors the proliferation and survival of the tumor cells.

*EDN1* and *EDN2* were the most prominently downregulated genes in MZ1774 cells on YAP knockdown. Endothelins are important regulators of kidney function, and endogenous endothelin is involved in the regulation of renal cell growth and proliferation, as well as fluid and electrolyte excretion. Production of endothelins in the kidney is increased in numerous renal diseases [@bb0160], and ccRCC tumors have been reported to express EDN1 and its receptor ET~A~ with ccRCC cell lines secreting EDN1 [@bb0165], [@bb0170]. The selective endothelin-A receptor antagonist atrasentan has been used in combination with interferon-alpha in a phase I study in metastatic RCC, albeit with moderate clinical antitumor effects [@bb0175].

The impact of YAP knockdown on EDN2 expression was most pronounced and present in all three cell lines tested, whereas EDN1 down-regulation could be cross-validated in A498 but not in ACHN YAP knockdown cells. As ACHN YAP knockdown cells displayed the same phenotype in respect to reduced cancer cell proliferation and migration and did form smaller xenograft tumors *in vivo*, EDN2 seems to be one of the main effectors responsible for these effects. In line with this hypothesis, we found that YAP and EDN2 expression correlates in clinical tumor specimen of patients with ccRCC as assessed by immunohistochemistry. Research on the endothelin axis in cancer has focused mainly on EDN1, and results have largely been extrapolated to EDN2. It has been assumed that EDN2 would mimic the actions of its more abundant counterpart EDN1, but recent findings *in vitro* and in knockout mice underscore that EDN2 does not simply amplify or duplicate EDN1 action and imply a distinct function of EDN2 in physiological and pathophysiological processes [@bb0180]. Furthermore, EDN2, and not the more abundant EDN1, was first isolated from RCC cell lines [@bb0185]. A recent paper reported EDN2 expression to be a common and early event in patients with localized ccRCC undergoing nephrectomy and proposed a potential role in ccRCC progression [@bb0190]. An association of higher tumor expression of EDN2 with longer progression-free survival could not be confirmed after adjustment for known clinicopathologic factors and it would be interesting to compare expression levels with tumors of patients with advanced metastatic disease.

Grimshaw et al. reported an important influence of EDN2 on the invasive potential of breast cancer cells and proposed a mechanism where EDN2-secreting tumor cells provide chemotactic cues to tumor-infiltrating macrophages, which in turn secrete matrix metallopeptidase (MMP)-2 and MMP-9 to facilitate tumor cell invasion and metastasis [@bb0195]. The observed effect was dependent on both endothelin receptor B and MAPK signaling, and expression of EDN2 and its receptor was stronger at the invasive margin of the tumor tissue. Of note, we observed inhibition of the MAPK signaling pathway on YAP knockdown in MZ1774 cells. Overexpression of EDN2 increases the invasive potential of breast cancer cell lines *in vitro* but is not sufficient to induce an invasive phenotype in benign cells, indicating the cooperation with other signaling networks [@bb0200].

Concurrently, Said et al. reported an instrumental role of EDN1 signaling through endothelin receptor A in the development of metastatic bladder cancer and delineated a proinvasive network governed by members of the endothelin family involving direct actions like the activation of proinflammatory transcription factors such as activator protein 1 and nuclear factor kappa-light-chain-enhancer of activated B cells in human monocytes and cancer cells and the stimulation of the production of a range of proinvasive cytokines like interleukin-6, cyclooxygenase 2, chemokine (C-C motif) ligand 2 (CCL2), MMP-2, and MMP-9 as well as indirect modulation of the tumor microenvironment by influencing tumor-stroma interactions as well as tumor-associated immune cells [@bb0205]. These endothelin functions were instrumental in the process of metastatic colonization, the first step of the establishment of a filial tumor at a distant site, and pharmacologic blockade of endothelin receptor signaling inhibited metastasis significantly in an experimental animal model, despite having only modest effects on primary tumor growth. We observed that these reported target genes of EDN1 signaling, namely *interleukin-6*, *COX2*, *VEGFA*, and *CCL2*, were also moderately but significantly downregulated in MZ1774 YAP knockdown cells as determined by microarray or RT-PCR analysis (fold changes were 0.74, *P* \< .0008 for interleukin-6, 0.60, *P* = .002 for COX2, 0.67, *P* = .0065 for VEGFA, and 0.82, *P* = .032 for CCL2, respectively).

Up-regulation of c-Myc expression has been reported to occur in a majority of ccRCC cases [@bb0210], [@bb0215], although amplification of the *MYC* gene is only found in a small subset of cases [@bb0210], [@bb0220] leading to the assumption that c-Myc is activated by other mechanisms in addition to amplification. We observed strong c-Myc down-regulation on YAP knockdown in MZ1774 cells. c-Myc knockdown by siRNA in ccRCC cell lines leads to a phenotype that resembles that of YAP knockdown with marked inhibition of proliferation and anchorage-independent growth [@bb0210]. c-Myc expression is stimulated by EDN1 through MAPK signaling in neoplastic cells [@bb0225], [@bb0230], and our data show inhibition of the MAPK signaling pathway along with EDN1 and concomitant c-Myc down-regulation on YAP knockdown in MZ1774 and A498 cells, whereas mRNA expression levels of these genes were not affected in ACHN cells, indicating that c-Myc might additionally be an indirect target of YAP, downstream of EDN1 in ccRCC. However, the *MYC*-promoter region features GT-IIC consensus sequences as potential binding sites for the YAP/TEAD complex, and indeed, these regions are enriched in ChIPs of MZ1774 lysates, underscoring the primary direct relationship. Previous studies have also found pronounced c-Myc up-regulation on overexpression of YAP in the murine liver [@bb0015].

CDH6 mRNA expression was found to be upregulated in MZ1774 YAP knockdown cells. Normal renal epithelium and RCC express multiple members of the cadherin family in a distinct pattern with E-cadherin being expressed in Bowman\'s capsule and all tubular segments except the proximal convoluted and straight tubules [@bb0235]. Consequently, E-cadherin expression frequency in RCC is lower than in other cancers and even low-grade tumors infrequently express E-cadherin [@bb0240]. Conversely, CDH6 is expressed in proximal renal tubules and RCC, especially when E-cadherin is absent, and seems partly to take over E-cadherin function [@bb0245]. Detectable CDH6 mRNA from circulating tumor cells in the peripheral blood of patients with RCC has been proposed as a prognostic marker associated with increased risk of metastasis [@bb0245], [@bb0250] hinting not necessarily at an active role of the CDH6 protein in metastasis but rather highlighting the inadequate ability of CDH6 to replace E-cadherin in cell adhesion. Up-regulation of the cell adhesion molecule CDH6 in response to YAP knockdown is therefore not contradictory to a less invasive phenotype.

In light of the most recent report published by the Cancer Genome Research Atlas Network [@bb0255], which found frequently altered promoter methylation of miR-21 with subsequent high miR-21 expression in high stage ccRCCs that inversely correlated with outcome, it is intriguing to note the significant down-regulation of miR-21 upon YAP knockdown. Recent work from Dey et al. showed that miR-21 targets PTEN protein expression and promotes ccRCC survival and invasion through Akt/TORC1 signaling [@bb0260].

Taken together, our data provide strong evidence that Hippo signaling plays an important role in regulating proliferation, invasiveness, and metastatic potential of ccRCC and might serve as a target for therapeutic intervention in the future. Disrupted Hippo signaling and consecutive derepression and activation of YAP lead to increased production of the putative YAP target genes *EDN1*, *EDN2*, and *c-Myc*. Increased endothelin signaling in turn results in increased production of proproliferative and proinvasive mediators by ccRCC cells and might thus enhance metastatic colonization. Therefore, future studies aimed at developing specific inhibitory drugs of the Hippo signaling pathway or its downstream effectors described here seem warranted to generate novel therapeutic regimens against ccRCC.
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[^1]: Fisher exact test, *P* = .0091.

[^2]: KEGG, Kyoto encyclopedia of genes and genomes; pNDE, probability value for overrepresentation of differentially expressed genes in a given pathway; pPERT, probability value for abnormal perturbation of that pathway, as measured by propagating measured expression changes across the pathway topology; pG, global probability value combining pNDE and pPERT; pGFDR, pG (after false discovery rate-correction); pGFWER, pG (after familywise error rate-correction).

[^3]: Fisher exact test, *P* = .0067.
